From: Medtronic
STAR 3 trial clinically validates the Medtronic integrated system
STAR 3 is a multicenter, randomized controlled trial that compared Medtronic’s sensor-augmented insulin pump (an integrated system using an insulin pump, continuous glucose monitoring (CGM) and therapy management software) to multiple daily injections (MDI). The data showed a statistically significant improvement in A1C across the age spectrum (adults, teens, and children) without increasing severe hypoglycemia.
http://www.minimed.com/star3/
2 thoughts on “Medtronic trial says pumps & CGM better than injections”